🇺🇸 FDA
Patent

US 11981716

Activatable interleukin-2 polypeptides and methods of use thereof

granted A61KA61K38/00A61P

Quick answer

US patent 11981716 (Activatable interleukin-2 polypeptides and methods of use thereof) held by Werewolf Therapeutics, Inc. expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Werewolf Therapeutics, Inc.
Grant date
Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K38/00, A61P, A61P35/00